RxDoctor Payments Data

Judith Brooks, MD

Family Medicine · Port St Lucie, FLNPI 1235398025

Payments from drug & device makers

$1,714in general payments, 2019–2025

Across 44 payments — averaging $38.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$488
  • AstraZeneca$342
  • GSK$266
  • Amgen$132
  • Otsuka America Pharmaceutical, Inc.$120
  • Astellas Pharma US Inc$110
  • plus $257 from 7 others

What the payments were for

  • Food & beverage$1,61994%
  • Education$956%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,714 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$67,161
Medicare patients
85
Services billed
437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$73,561
EliquisApixaban55$53,190
MounjaroTirzepatide41$44,913
JanuviaSitagliptin Phosphate39$37,025
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$32,087
JardianceEmpagliflozin29$31,452
TrulicityDulaglutide16$19,614
JanumetSitagliptin Phos/Metformin Hcl12$14,761
XareltoRivaroxaban18$14,588
Memantine Hcl47$2,680
Valsartan54$2,609
Atorvastatin Calcium158$2,465
Rosuvastatin Calcium108$2,294
Levocetirizine Dihydrochloride92$2,251
SynthroidLevothyroxine Sodium30$2,029

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$488$73,56152 claims
Lilly USA, LLCMounjaro, Trulicity$40$64,52657 claims
GSKTrelegy Ellipta$266$32,08733 claims
Johnson & JohnsonXarelto$65$14,58818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Port St Lucie

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →